

## Information on the Annual Financial Statements 2025

**Paris (France) and Cambridge (Massachusetts, USA), May 29, 2026 – 10:00 PM (CET)** – Biophytis SA (Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, hereby informs the market, further to its press release dated April 29, 2026, that the work required to finalize the 2025 annual accounts and to prepare the audit procedures is still ongoing and will not allow publication of the accounts within the previously announced timeframe.

This delay is primarily due to the need for the Company to complete its year-end closing procedures, the preparation of the consolidated financial statements, and the preparatory work required prior to the formal commencement of audit procedures with the statutory auditors. The Company is actively engaged in discussions with its statutory auditors to enable, once all conditions necessary for the audit to commence have been met, the completion of the audit work as promptly as possible.

The Company and its statutory auditors remain fully committed to conducting the audit work in a manner consistent with the quality, reliability, and compliance standards applicable to the statutory audit of annual accounts.

The Company is also in ongoing dialogue with the relevant market authorities. It wishes to remind the market that, pursuant to applicable market rules, failure to publish the annual accounts within the regulatory deadlines may result in the suspension of trading in the Company's shares by Euronext.

In this context, the Company will not be in a position to hold its ordinary general meeting of shareholders within the statutory timeframe. Notice of such meeting will be given at a later date in accordance with applicable legal and regulatory requirements. The Company will, as soon as possible, initiate the necessary legal proceedings to account for this postponement.

### About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company's ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit [www.biophytis.com](http://www.biophytis.com).

### Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important

## Press release

factors that could cause actual outcomes or results to differ materially from those indicated in these statements.

Please also refer to the "Risk and uncertainties the Company is to face" section from the Company's 2023 Financial Report available on BIOPHYTIS website ([www.biophytis.com](http://www.biophytis.com)) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

### **Biophytis Contacts**

Investor Relations

[Investors@biophytis.com](mailto:Investors@biophytis.com)

### **US Investors**

### **Media contacts**

Antoine Denry: [antoine.denry@taddeo.fr](mailto:antoine.denry@taddeo.fr) – +33 6 18 07 83 27

Nizar Berrada : [nizar.berrada@taddeo.fr](mailto:nizar.berrada@taddeo.fr) - +33 6 38 31 90 50